Study identifier:D5130C00078
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study
Coronary heart disease
Phase 3
No
90 mg Ticagrelor, 75mg Clopidogrel
All
0
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 May 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Ticagrelor 90 mg Ticagrelor | Drug: 90 mg Ticagrelor Morning and Evening dose for 5 days |
Active Comparator: Clopidogrel 75mg Clopidogrel | Drug: 75mg Clopidogrel Morning dose for 5 days |